Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE SELF-MEDICATION NEWS IN BRIEF
July 30, 2007
-
ARCHIVE NPhA to Further Promote Use of Generics
July 30, 2007
-
ARCHIVE OPINION/Once in a Lifetime
July 30, 2007
-
ARCHIVE MD Studies to Be Permitted at a Total Dose of 500 μg: Dr Ohno
July 30, 2007
-
ARCHIVE TOPICS/Mebix Starts Home Blood Pressure Management Service
July 30, 2007
-
ARCHIVE RIKEN, Harvard Univ. Hospital Decipher Protein Structure of LTC4 Synthase
July 30, 2007
-
ARCHIVE Nutrition Management Improves QOL, Reduces Costs: Prof. Ohyanagi
July 30, 2007
-
ARCHIVE Otsuka, GW Pharmaceuticals Sign Joint Research Agreement
July 23, 2007
-
ARCHIVE Wyeth Japan Committed to Catching Up with the Rest of the World
July 23, 2007
-
ARCHIVE REGULATORY NEWS IN BRIEF
July 23, 2007
-
COMMENTARY COMMENTARY/Range of Drugs Re-priced due to Expansion of Market May Be Expanded
July 23, 2007
-
ARCHIVE Exelon Patch Approved for Alzheimer's Disease: Novartis
July 23, 2007
-
ARCHIVE Price Agreement Rate Rose to 92.4% as of End of March
July 23, 2007
-
ARCHIVE R&D NEWS IN BRIEF
July 23, 2007
-
ARCHIVE Promote Multinational Clinical Trials to Eliminate Drug Lag: Study Group
July 23, 2007
-
ARCHIVE NEW PRODUCTS
July 23, 2007
-
ARCHIVE Profits Should Be Transferred from Long-Listed Drugs to New Drugs: Mr Yamabe
July 23, 2007
-
ARCHIVE New CRT-D Concerto C154DWK, ICD Virtuoso VR: Medtronic
July 23, 2007
-
ARCHIVE JPMA Proposes “Reported Price Approval System” for New Drugs
July 23, 2007
-
ARCHIVE EnRhythm Automatically Selects Optimal Pacing Mode: Medtronic
July 23, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…